Opinion|Videos|May 6, 2024
A New Era in PAH Treatment?
Author(s)Marius Hoeper, MD
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AI Chatbots Score Below 28% on Colorectal Cancer Questions
2
5 Notable FDA Approvals From the First Half of 2026
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
5